The medical technology company behind a molecular diagnostic test that can detect both influenza viruses and coronaviruses in two to three hours said it received emergency use authorization from the FDA on Friday.

Becton, Dickinson & Company (BD), stated Its test, which runs on the company’s existing BD Max platform, is also able to detect UK and South African coronavirus variants with 99.9% accuracy.

“A computer analysis showed that 99.9% of these variants are a similar match to at least two molecular targets for genetic sequence testing,” the company said in a news release. “This ability to detect these new variants also applies to the standalone SARS-CoV-2 test for the BD Max system.”

Is there a limit for coronaryvus mutations?

The test, which also detects influenza A and B strains, provides positive or negative results for each virus using a single sample. Company said Thousands of laboratories worldwide are already using the BD Max System diagnostic platform, and that each unit is capable of analyzing hundreds of samples over a 24-hour period.

“Our clinical solutions for COVID-19 and the flu can rapidly contribute to timely diagnosis and ultimately patient management and treatment,” said Dave Hickey, president of Life Sciences for BD. In a news release. “In addition, the new information provided on the ability of the test to detect UK and South African variants provides useful guidance to health care practitioners as we look to identify and incorporate these new strains.”

Click here for complete coronary coverage

The company said it also received a CE mark, indicating approval in the European Union.